Multiple Myeloma Coverage from Every Angle


Steroid-Free Combination Therapy Under Study in Multiple Myeloma
AACR 2024: Study Reports Activity With Linvoseltamab in Resistant Myeloma
Expanded FDA Approval for Idecabtagene Vicleucel in Relapsed or Refractory Multiple Myeloma
Optimizing Pomalidomide-Based Therapy for Relapsed or Refractory Multiple Myeloma
Risk of Relapse: Predictions Among Patients With Ultra–High-Risk Multiple Myeloma
Biweekly Dosing Approved by the FDA for Teclistamab-cqyv in Multiple Myeloma
DREAMM-7 Supports Novel Triplet Regimen in Relapsed or Refractory Multiple Myeloma
Understanding the Clinical Impact of Progressive Smoldering Multiple Myeloma
Initial Trial Results With Novel Combination Therapy for Resistant Myeloma
Is There a Future for Microbiota-Based Treatment in Resistant Multiple Myeloma?
FDA Calls for New Boxed Warning on All CAR T-Cell Therapies
Early Results With Bispecific T-Cell Engager in High-Risk Smoldering Myeloma
NCCN Awards Grants to Study Use of BCMA-Directed Bispecific Antibody in Multiple Myeloma
Has the Risk of Infection Shifted in the Era of Novel Multiple Myeloma Agents?
New BCL2 Inhibitor Plus Dexamethasone Under Study in Relapsed or Refractory Multiple Myeloma
Can Revised FLC Reference Intervals Improve Diagnosis of Light Chain MGUS?
MonumenTAL-1 Trial: Intensity of Dosing With Talquetamab in Myeloma Under Study
Comparing Infections Rates With Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma
ASH 2023: Four-Drug vs Three-Drug Regimens Before and After ASCT in Myeloma
ASH 2023: Quadruplet Regimen Followed by Doublet Maintenance Improves Outcomes in Multiple Myeloma
ASH 2023: Final CENTAURUS Analysis Supports Daratumumab’s Role in Smoldering Myeloma
ASH 2023: Using Inflammatory Biomarkers to Predict Response to CAR T-Cell Therapy
ASH 2023: MRD Negativity With Triplet Therapy in Transplantation-Ineligible Patients With Myeloma
ASH 2023: Large Real-World Study of Bispecific T-Cell Engager in Resistant Myeloma
ASH 2023: Four Drugs, Two Transplants, One Study’s Results in High-Risk Myeloma
Long-Term Study Gets to the Heart of Cardiovascular Issues After HSCT
Daratumumab-Based Regimen for Lenalidomide-Refractory Myeloma: An Italian Perspective
OCEAN and HORIZON Trials: More Benefit Than Risk With Melflufen Plus Dexamethasone in Myeloma?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.